17:38 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest CLRN1 gene therapy could help treat hearing loss in Usher syndrome type 3A, which is caused by CLRN1 mutations. In a hair cell-specific CLRN1 knockout mouse model of Usher...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
15:46 , Jul 11, 2017 |  BC Extra  |  Preclinical News

Amino acid transporter linked to depression

In a paper published in The Journal of Neuroscience, scientists showed that reduction of solute carrier family 6 member 15 (SLC6A15), a neutral amino acid transporter, in the nucleus accumbens is linked to increased susceptibility...
18:43 , Feb 1, 2017 |  BC Innovations  |  Emerging Company Profile

Evoking exosomes

Exosomes are emerging as one of the newest technologies for creating diagnostics and delivering therapeutics, primarily in cancer. Evox Therapeutics Ltd. is joining the growing list of start-ups, using science from exosome pioneer Matthew Wood...
07:00 , Oct 18, 2016 |  BC Extra  |  Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
07:00 , Oct 13, 2016 |  BC Extra  |  Clinical News

NeuroVive slides after dropping CicloMulsion for AKI

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) fell SEK2.68 (44%) to SEK3.42 on Thursday after the company said it will discontinue development of CicloMulsion for acute kidney injury. The therapy missed the primary endpoint and had "no...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Dengvaxia tetravalent dengue vaccine regulatory update

Costa Rica approved Dengvaxia from Sanofi’s Sanofi Pasteur vaccines division to prevent dengue fever infection in people ages 9-45 living in endemic areas. The vaccine is approved in Mexico, Brazil, El Salvador and the Philippines....
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

IntelGenx, RedHill, Juste deal

IntelGenx and Redhill granted Juste exclusive rights to commercialize migraine drug Rizaport rizatriptan in Spain and a right of first refusal in Belize, the Caribbean, Chile, Colombia, Costa Rica, the Dominican Republic, El Salvador,...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipocalin (NGAL; LCN2)

Renal disease INDICATION: Renal Patient sample and mouse studies suggest 4-phenylbutyric acid could help treat proteinuria associated with chronic kidney disease. Renal tubule levels of NGAL were higher in patients with proteinuric nephropathy and mouse models of...